Verrica Pharmaceuticals Inc.
As of Oct 22, 2026, Verrica Pharmaceuticals is in Stage 4, the downtrend phase, now in week 14 (since Jul 22, 2026). It closed at $3.83, 57.9% below its 52-week high and below its 200-day average, which is falling.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is VRCA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VRCA among Biotechnology202nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …202 | VRCA | Stage 4 · wk 14 | 50 | −17.1% |
Verrica Pharmaceuticals: quick answers
What stage is Verrica Pharmaceuticals in?
As of Oct 22, 2026, Verrica Pharmaceuticals (VRCA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 22, 2026 and is in week 14. What the four stages mean
Is Verrica Pharmaceuticals in an uptrend?
No. Verrica Pharmaceuticals is in a Stage 4 downtrend. It trades 33.3% below its 200-day average, which is falling.
How far is Verrica Pharmaceuticals from its 52-week high?
Verrica Pharmaceuticals closed at $3.83 on Oct 22, 2026, 57.9% below its 52-week high of $9.10. Its 52-week low is $3.28.
How has Verrica Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Verrica Pharmaceuticals is down 5.2% over the past year and down 53.9% so far in 2026.
Which sector and industry is Verrica Pharmaceuticals in?
Verrica Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.